The approved medicine for malaria has not yet existed for babies, but now Novartis has introduced the Coartem Baby or Riamet Baby.
The first drug for malaria, suitable for infants and very young children, has been approved for use. It will begin to use it in African countries in the coming weeks. The BBC reported it.
The media record has not yet approved a malaria medicine for infants. Such children are treated with versions developed for older children, creating excessive risk.
In 2023 – the year, where the latest data is available – malaria is associated with nearly 597,000 deaths. Almost all deaths took place in Africa, and almost three quarter of them were children under the age of five.
Experts say this leads to the so -called “treatment space.”
Today the new drug developed by the Pharmaceutical Pharmacist company Novartis has been approved by the Swiss authorities and may be introduced to regions and countries with the highest malaria range in a few weeks.
Novartis plans to introduce it on a basic basis.
The drug, known in some countries as Coartem Baby or Riamet Baby, was developed by Novartis in collaboration with drugs for malaria venture (MMV), the Swiss non -profit organization, originally supported by the UK governments, Switzerland and the Netherlands, as well as the World Bank and the Fund Rockeller.
Eight countries in Africa also participated in the assessment and test of the drug.
Remember that in May they registered a deadly case of tropical malaria throughout the region.
Who: The number of malaria cases has grown 11 million
News from CORRESPONDENT.NET On the telegram and whatsapp. Subscribe to our channels https://t.me/KorresPondentNet and WhatsApp
Source: korrespondent
I am Ben Stock, a passionate and experienced digital journalist working in the news industry. At the Buna Times, I write articles covering technology developments and related topics. I strive to provide reliable information that my readers can trust. My research skills are top-notch, as well as my ability to craft engaging stories on timely topics with clarity and accuracy.